The annual direct medical costs of patients with chronic migraine approach $5000, and the costs associated with lost productivity exceed $3000 annually.
Migraine is the third most common medical condition and the eighth leading cause of disability worldwide, according to the World Health Organization; yet, migraines are still underdiagnosed and undertreated. The misdiagnosis of migraines is partly to blame for patients not receiving optimal care.
Philadelphia, PA—Two investigational monoclonal antibodies against the calcitonin gene-related peptide (CGRP) proved safe and effective at preventing migraine in a pair of phase 2, placebo-­controlled, proof-of-concept trials, researchers reported at the 2014 American Academy of Neurology meeting.
Philadelphia, PA—A breath-powered intranasal powder form of sumatriptan produces fast and sustained relief of migraine, according to the results of a phase 3, placebo-controlled trial presented at the 2014 American Academy of Neurology meeting.
Blinding of patients to their assigned treatment (active or placebo) is a standard procedure in clinical trials to assess the “true” efficacy of the active drug. But what happens when patients are certain whether they are receiving active treatment or placebo?

Results 1 - 5 of 5
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology